Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.

Herrera C, Armanasco N, García-Pérez J, Ziprin P, Olejniczak N, Alcamí J, Nuttall J, Shattock RJ.

AIDS. 2016 Apr 24;30(7):1015-25. doi: 10.1097/QAD.0000000000001043.

2.

Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.

Fletcher P, Herrera C, Armanasco N, Nuttall J, Shattock RJ.

AIDS Res Hum Retroviruses. 2016 Apr;32(4):334-8. doi: 10.1089/AID.2015.0315. Epub 2016 Jan 29.

3.

Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Stefanidou M, Herrera C, Armanasco N, Shattock RJ.

Antimicrob Agents Chemother. 2012 Aug;56(8):4381-90. doi: 10.1128/AAC.00399-12. Epub 2012 Jun 4.

4.

Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Harman S, Herrera C, Armanasco N, Nuttall J, Shattock RJ.

Antimicrob Agents Chemother. 2012 May;56(5):2347-56. doi: 10.1128/AAC.06108-11. Epub 2012 Feb 13.

5.

Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R.

Antimicrob Agents Chemother. 2009 Feb;53(2):487-95. doi: 10.1128/AAC.01156-08. Epub 2008 Nov 24.

Supplemental Content

Loading ...
Support Center